A combination of high folate with low vitamin B 12 plasma status has been associated with cognitive impairment in a population exposed to mandatory folic acid fortification. The objective of the present study was to examine the interactions between plasma concentrations of folate and vitamin B 12 markers in relation to cognitive performance in Norwegian elderly who were unexposed to mandatory or voluntary folic acid fortification. Cognitive performance was assessed by six cognitive tests in 2203 individuals aged 72-74 years. A combined score was calculated using principal component analysis. The associations of folate concentrations, vitamin B 12 markers (total vitamin B 12 , holotranscobalamin (holoTC) and methylmalonic acid (MMA)) and their interactions in relation to cognitive performance were evaluated by quantile regression and least-squares regression, adjusted for sex, education, apo-14 genotype, history of CVD/hypertension and creatinine. Cross-sectional analyses revealed an interaction (P¼0·009) between plasma concentrations of folate and vitamin B 12 in relation to cognitive performance. Plasma vitamin B 12 concentrations in the lowest quartile (, 274 pmol/l) combined with plasma folate concentrations in the highest quartile (.18·5 nmol/l) were associated with a reduced risk of cognitive impairment compared with plasma concentrations in the middle quartiles of both vitamins (OR 0·22, 95 % CI 0·05, 0·92). The interaction between folate and holoTC or MMA in relation to cognitive performance was not significant. In conclusion, this large study population unexposed to mandatory folic acid fortification showed that plasma folate, but not plasma vitamin B 12 , was associated with cognitive performance. Among the elderly participants with vitamin B 12 concentrations in the lower range, the association between plasma folate and cognitive performance was strongest.
performance might be modified by blood concentrations of the other B-vitamin. In line with this, cross-sectional analyses within the National Health and Nutrition Examination Survey (NHANES) study revealed that high serum folate status was generally associated with protection against cognitive impairment; however, individuals with low vitamin B 12 status combined with high folate status had an increased risk of cognitive impairment compared with those with a normal status of both vitamins (7) . It has been hypothesised that unmetabolised folic acid, which is likely to be present in individuals living in areas with mandatory folic acid fortification of food items (8, 9) , may mask or exacerbate metabolic and clinical consequences of vitamin B 12 deficiency (10) . The findings from the NHANES study that high folate concentrations were associated with an increased risk of cognitive impairment in individuals with vitamin B 12 deficiency are in line with the results from the Framingham Heart Study including individuals unexposed to folic acid fortification (11) .
In other large study populations unexposed (12, 13) or exposed (14) to mandatory folic acid fortification, the NHANES findings could not be confirmed. These previous studies differed from the NHANES study in several aspects. First, they used a lower cutoff value for high folate concentrations; second, they used only one or two cognitive performance tests; third, they may have lacked power; and fourth, they measured a single marker of vitamin B 12 status, either total vitamin B 12 or holotranscobalamin (holoTC) II. HoloTC II refers to the fraction of circulating vitamin B 12 bound to the transporter protein transcobalamin which delivers the vitamin into the cells, and it has been suggested to be a more sensitive and specific marker of vitamin B 12 status than total concentrations of vitamin B 12 in plasma (15) . It remains unclear whether the combination of high folate and low vitamin B 12 status worsens cognitive performance when compared with that of normal folate and normal vitamin B 12 status. We therefore investigated the interaction between various markers of vitamin B 12 and folate status in relation to cognitive performance based on six cognitive tests in a large population-based study not exposed to mandatory or voluntary food fortification with folic acid.
Methods

Study population
The study population consisted of apparently healthy residents of Bergen (Norway) born between 1925 and 1927, who participated both in the Hordaland Homocysteine Study in 1992-3 and in the Hordaland Health Study in 1997-9 (http://www.husk.b.uib.no). A total of 2841 communitydwelling elderly individuals were invited to participate in a substudy on cognitive tests in 1997-9, of whom 2203 (77·5 %) agreed. Details of this study have been described elsewhere (16 -18) . The study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by the Regional Committee for Medical Research Ethics of Western Norway. Written informed consent was obtained from all the subjects.
Assessment of cognitive performance
Cognitive performance was assessed at the study location by trained nurses and included six tests (19) : a modified version of the Mini-Mental State Examination (m-MMSE; global cognition, maximum score 12) (20, 21) ; a modified version of the Digit Symbol Test (perceptual speed, score reflects the number of digits recalled) (22) ; a short form of the Block Design (visuospatial skills, maximum score 16) (22) ; the Kendrick Object Learning Test (episodic memory, maximum score 70) (23) ; an abridged version of the Controlled Oral Word Association Test (access to semantic memory, score reflects the number of words recalled) (24) ; the Trail Making Test Part A (executive function, score reflects the number of seconds needed to complete the task) (25) . For all tests, a higher score indicates better performance, except for the Trail Making Test Part A where a shorter time used indicates better performance.
Other covariates
Both in 1992-3 and 1997-9, participants underwent a brief health examination including measurements of height and weight. In addition, information on cardiovascular risk factors and lifestyle factors including smoking status (current smokers, ex-smokers or never smokers), consumption of coffee (0-1, 1 -4 or more than five cups/d), alcohol use (number of glasses/week) and use of multivitamin or B-vitamin supplements was collected via self-administered questionnaires, as described previously (17, 26) . Users of folic acid supplements were included in the study. Dietary intakes of folate and vitamin B 12 were measured in 1997-9 by a quantitative FFQ (27) . History of CVD was based on self-reported information on the history of myocardial infarction, angina pectoris and stroke as recorded both in 1992-3 and 1997-9, and on the history of thrombosis and phlebitis as recorded in 1992-3. Of the self-reported CVD cases, 79 % were validated with hospitalisation records used in an earlier study (28) , whereas the remaining 21 % were presumably less severe and did not require hospitalisation or occurred before 1992. A history of hypertension was defined as current or previous use of antihypertensive drugs, and was based on self-reported data collected in 1997-9. Diabetes was based on self-reported information collected in 1997-9. Depression score was assessed in 1997-9 by a seven-item subscale for depression from the Hospital Anxiety and Depression Scale depression subscale (HADS-D) (29) . Educational level was classified as no primary school, primary school (# 9 years), vocational secondary school (10 -12 years), theoretical secondary school (10 -12 years), college or university (, 4 years), and college or university ($ 4 years).
Plasma measurements
Non-fasting EDTA blood samples were collected for the analyses of plasma markers of folate and vitamin B 12 status. The EDTA samples were kept at 48C until centrifugation. Samples collected in 1992 -3 were stored at 2208C for up to 10 years, whereas samples collected in 1997-9 were stored at 2808C for up to 12 months before analyses. Plasma concentrations of folate and vitamin B 12 were determined by microbiological assays (30, 31) . A recent study has shown that folate concentrations in plasma are not stable during storage (32) . However, folate determined as p-aminobenzoylglutamate (pABG) equivalents only decreases slowly during storage. We therefore measured pABG equivalents using liquid chromatography -MS/MS in 200 randomly selected samples collected in 1992-3 and 1997-9 (32) . Based on the results of these analyses, we corrected for folate degradation during storage by using separate correction factors for the samples collected at baseline (corrected folate concentration 1992-3 ¼ 5·3373 þ 1·4045 £ folate concentration measured in 1992-3) and those collected at follow-up (corrected folate concentration 1997-9 ¼ 8·051 þ 1·101 £ folate concentration measured in 1997-9).
Plasma concentrations of methylmalonic acid (MMA), an inverse marker for vitamin B 12 status (33, 34) , were determined by a modified GC -MS method based on ethylchloroformate derivatisation (35) , and plasma concentrations of holoTC II were analysed by microbiological assays (36) . These indicators of vitamin B 12 status were only measured in the samples collected in 1997-9.
Plasma total homocysteine (tHcy) concentration was determined using an automated HPLC assay (37, 38) . Within-day CV for plasma measurements were ,5 % for concentrations of folate, vitamin B 12, MMA, holoTC II and tHcy.
Serum creatinine levels were analysed in the samples collected in 1997-9 by a modification of a liquid chromatography -MS/MS procedure (39) . ApoE-14 genotypes (0, 1 or 2 apoE-14 alleles) were determined using a one-stage PCR method (40) , and methylenetetrahydrofolate reductase genotyping (677C ! T) was performed by a real-time PCR (41) .
Statistical analyses
Descriptive analyses. Plasma concentrations of folate and vitamin B 12 measured in 1992 -3 and 1997-9 were compared with a paired sample t test. Relationships between the different markers of vitamin B 12 status measured in 1997-9 were evaluated with Spearman's correlation tests. Principal component analysis (PCA) was used to create a summary score for cognitive performance that accounted for the correlations between the different cognitive performance tests and, thereby, maximised the explained variance. The number of components to be retained was determined according to two criteria: (1) eigenvalues . 1 and (2) Cattell's scree plot which shows the total variance related to each component. For comparison of cognitive performance on the individual tests across the quartiles of the cognitive performance component created with PCA, univariate ANOVA was used.
Quantile regression analyses. In order to investigate the interactions between folate and markers of vitamin B 12 status in relation to cognitive performance, multivariate quantile regression and ordinary least-squares regression were used including the cognitive performance component extracted with PCA as the dependent variable. Interactions between folate and markers of vitamin B 12 status in relation to cognitive performance were assessed with models including folate, a marker for vitamin B 12 status, and their product term reflecting interaction, as continuous, independent variables. The quantile regression technique was used to provide distribution-free tests of whether the associations between folate, vitamin B 12 markers and their interactions vary along the cognitive performance distribution. Plasma concentrations of folate and markers of vitamin B 12 status were expressed as standardised z-scores to provide comparable associations per SD increase.
Logistic regression analyses. We further studied the interaction by estimating OR for cognitive impairment according to categories of combined folate and vitamin B 12 status using logistic regression analyses. Cognitive impairment was defined as the lowest 10th percentile of the combined cognitive performance component as derived from the PCA. We determined quartiles for the markers of folate and vitamin B 12 status, and defined the first quartile as 'low', the fourth quartile as 'high' and the two middle quartiles as 'normal'. Categories were created in which we combined 'low', 'normal' or 'high' folate status with 'low', 'normal' or 'high' vitamin B 12 status. The combination of normal folate and normal vitamin B 12 status was used as the reference group. All analyses were adjusted for sex, education level, history of CVD/hypertension, apoE-14 genotype and creatinine. These covariates were strong predictors for cognitive performance or associated with both B-vitamin levels and cognitive performance, as demonstrated with ANOVA or Pearson's correlation coefficients. BMI, smoking status, consumption of coffee, alcohol use, methylenetetrahydrofolate reductase 677 C ! T genotype, diabetes and depression score were associated with either plasma folate or the markers of vitamin B 12 or with cognitive performance, but adjusting for these biological and lifestyle factors did not markedly change the results of the analysis, and are therefore not included in the final model.
Descriptive analyses and PCA were performed using SAS version 9.2 (SAS Institute Inc.). Quantile regression analyses were performed in R version 2.13.1 (R Foundation for Statistical Computing) using the package 'quantreg'. Multiple imputation of missing values was carried out by chained equations with fully conditional specifications using the package 'mice'. P values , 0·05 were considered as statistically significant.
Results
Characteristics of the study population
The characteristics of the study population in 1997-9 are presented in Table 1 . The mean age of the participants was 72·5 years and 44·9 % were men. Of the participants, about onehalf (51 %) reported a history of CVD, 17 % suffered from depressive symptoms as indicated by a HADS-D score $ 8 and 14 % were current smokers. The median plasma folate concentration measured in 1992-3 was 12·5 (5th -95th percentile 8·7-20·9) nmol/l after correction for folate degradation during storage, which was lower than the concentration measured in 1997-9 (median 15·8 (5th -95th percentile 12·0-34·0) nmol/l) (P for difference ,0·0001). The median Spearman's correlations (r) between plasma concentrations in 1992-3 and 1997-9 were 0·41 (P,0·0001) for folate and 0·63 (P, 0·0001) for vitamin B 12 . Plasma vitamin B 12 (in 1997-9) correlated significantly with holoTC II (r 0·66, P, 0·0001) and MMA (r 20·20, P, 0·0001), and holoTC II also correlated significantly with MMA (r 20·24, P,0·0001). Furthermore, in individuals with vitamin B 12 concentrations , 274 pmol/l, holoTC II concentrations were decreased and MMA and tHcy concentrations were elevated compared with individuals with vitamin B 12 concentrations .274 pmol/l (Table S1 , available online). tHcy concentrations were not elevated in participants with high folate concentrations (.18·5 nmol/l) compared with those with folate concentrations # 18·5 nmol/l.
Cognitive performance factors
Median (5th -95th percentile) scores for the six cognitive performance tests are presented in Table 1 . Based on m-MMSE scores #10 (19) , 36 % of the study population suffered from mild cognitive impairment. Eigenvalues and Cattell's scree plot revealed that one component derived by the PCA should be retained, explaining 40·5 % of the total variance, whereas factors 2 -4 explained less than 14·6 % each. The factor loading matrix is presented in Table S2 (available online). The first component strongly correlated with all six cognitive tests performed and is further referred to as 'overall cognitive performance'. Overall cognitive performance scores ranged from 2 4·80 to 2·49 with a mean of 0 and a SD of 1. Across the increasing quartiles of overall cognitive performance, the subjects performed better on each individual cognitive test (for all tests, P for difference ,0·0001; data not shown).
Cross-sectional associations of plasma concentrations of folate and vitamin B 12 markers with overall cognitive performance assessed in 1997-9 Fig. 1 shows that plasma vitamin B 12 is directly associated with cognitive performance at the lower quantiles of the cognitive performance distribution and inversely associated at the upper quantiles of the distribution. However, overall, this association is not significantly different from zero. Furthermore, Fig. 1 indicates a significant direct association of plasma folate, and a significant inverse interaction between plasma concentrations of folate and vitamin B 12 in relation to cognitive performance. The associations of sex (male v. female), education (direct), history of CVD/hypertension (inverse) and apoE-14 status (inverse) with overall cognitive performance were as expected (42) . Notably, the associations of folate, education and apoE-14 with overall cognitive performance were asymmetric with the strongest effects in the lowest ranges of the overall cognitive performance scores. (32) as explained in the Methods section.
When including holoTC II or MMA instead of plasma vitamin B 12 in the model, the quantile regression plots showed non-significant associations between holoTC II and MMA, a non-significant interaction between plasma folate and vitamin B 12 markers, but similar associations of the other covariates (data not shown). Table 2 presents the multivariate-adjusted ordinary leastsquares regression estimates for the associations of plasma folate concentrations and the markers of vitamin B 12 , as well as the interaction between plasma folate concentrations and the markers of vitamin B 12 in relation to the overall cognitive performance score. In agreement with Fig. 1 , plasma folate was directly associated and plasma vitamin B 12 was not associated with the overall cognitive performance score. The negative interaction between plasma concentrations of folate and vitamin B 12 indicates that the linear association between plasma folate and the overall cognitive performance score changes at different plasma concentrations of vitamin B 12 and vice versa. The observed association for the interaction term suggests that, among the elderly with vitamin B 12 concentrations in the lower range of the population, for example 2 SD below the mean, the association between plasma folate and the overall cognitive performance changes from b ¼ 0·097 to b ¼ 0·097 2 2 £ (20·058) ¼ 0·213, indicating that the positive effect of plasma folate concentrations on cognition becomes stronger at lower vitamin B 12 concentrations. In contrast, among the elderly with vitamin B 12 concentrations, 2 SD above the mean, the significant positive association between plasma folate and the overall cognitive performance changes from 0·2  0·4  0·6  0·8  0·2  0·4  0·6  0·8  0·2  0·4  0·6  0·8   0·2  0·4  0·6  0·8  0·2  0·4  0·6  0·8  0·2  0·4  0·6  0·8   0·2  0·4  0·6  0·8  0·2  0·4  0·6  0·8  0·2  0·4  0·6  0·8 Quantiles of the cognitive score (20·058) ¼ 2 0·019, indicating that the positive effect of plasma folate concentrations on cognition is slightly reduced. The vitamin B 12 markers MMA and holoTC II did not show significant associations with the overall cognitive performance factor, nor were any of the interactions with folate significant (Table 2) . We further evaluated the observed interaction between plasma concentrations of folate and vitamin B 12 using logistic regression analysis (Table 3) . Plasma vitamin B 12 concentrations in the lowest quartile of its distribution (,274 pmol/l) in combination with plasma folate concentrations in the highest quartile (.18·5 nmol/l) (n 102) when compared with normal plasma concentrations in the second and third quartiles of both vitamins (n 549) were associated with a reduced risk of cognitive impairment (OR 0·22, 95 % CI 0·05, 0·92).
Prospective associations of plasma concentrations of folate and total vitamin B 12 in 1992-3 with cognitive performance assessed in 1997-9
Multivariate quantile regression and ordinary least-squares regression revealed no significant associations of plasma folate (b ¼ 0·019, SE ¼ 0·031, P¼0·540) or plasma vitamin B 12 (b ¼ 0·020, SE ¼ 0·033, P¼ 0·541) measured in 1992 -3 along the distribution of overall cognitive performance. In addition, the interaction between plasma folate and vitamin B 12 sampled 6 years before the measurement of overall cognitive performance was not significant (b ¼ 0·024, SE ¼ 0·028, P¼0·394; data not shown).
Discussion
The present population-based study investigated the hypothesis that high folate status in combination with low vitamin B 12 status increased the risk for cognitive impairment, as was observed within the NHANES study (7) , and was conducted in a population that was not exposed to mandatory or voluntary fortification of food items with folic acid. The study, which included 2203 elderly people aged 71 -74 years, revealed that plasma folate, but not plasma vitamin B 12 , was associated with better cognitive performance. Although the subgroup was rather small, a combination of plasma folate .18·5 nmol/l with vitamin B 12 , 274 pmol/l was associated with a reduced risk of cognitive impairment when compared with having normal concentrations of both vitamins.
Methodological considerations
It has been suggested that folate and vitamin B 12 are related to different cognitive outcomes, and that there may even also be a difference in outcomes related to indicators of functional vitamin B 12 status (MMA and holoTC II) v. total concentrations of vitamin B 12 in plasma (43) . A major strength of the present study is the use of an extensive cognitive test battery covering global cognition, perceptual speed, visuospatial skills, episodic memory, access to semantic memory and executive function. We derived a cognitive performance component by the PCA, which is a robust measure for cognitive performance that reduces the possibility of measurement error and chance findings (44, 45) . There is currently no 'gold standard' to define vitamin B 12 deficiency with respect to potential markers and cut-off points to be used (46, 47) , although it has been recommended to include holoTC II and MMA as additional markers of vitamin B 12 status (48) . Fedosov (49) presented a mathematic model combining the concentrations of vitamin B 12 , MMA, holoTC II and tHcy to classify vitamin B 12 status without the use of pre-defined cut-off levels. In addition, single markers were examined for their potential to predict vitamin B 12 deficiency. They showed concentrations of holoTC II and 
HoloTC, holotranscobalamin; MMA, methylmalonic acid. * Ordinary least-squares regression coefficients adjusted for sex, education, apoE-14 status, history of CVD/hypertension and creatinine. † Standardised B-vitamin concentrations (z-scores). ‡ The coefficient for the product term indicates how the association between folate status and the cognitive performance score changes when the concentration of the marker for vitamin B 12 status increases. § Education level is defined as follows: no primary school; primary school (#9 years); vocational secondary school (10-12 years); theoretical secondary school (10-12 years); college or university (, 4 years); college or university ($4 years).
MMA to be more reliable than vitamin B 12 or tHcy concentrations for predicting vitamin B 12 deficiency. Vogiatzoglou et al. (50) observed that vitamin B 12 concentrations below 400 pmol/l were associated with elevated concentrations of tHcy and MMA in the Hordaland Health cohort. In line with this, it has been suggested that desirable blood vitamin B 12 concentrations may be higher than the current clinical recommendations since many studies have observed associations between 'low -normal' vitamin B 12 and several negative health outcomes (51) . To avoid the use of cut-off levels for low vitamin B 12 status, elevated folate status and cognitive impairment, as for the latter two, a consensus definition is lacking as well, we performed the present analyses by quantile regression, in which we plotted the associations between B-vitamins and the overall cognitive score through the distribution of the overall cognitive score. To facilitate comparison with the literature, we additionally created population-based quartile categories to define high and low concentrations of B-vitamins.
Our study group previously demonstrated that folate is degraded in stored samples to compounds that are almost completely recoverable as pAGB (32) . In the present study, we used the pABG assay (52) in a subsample and subsequently corrected for folate degradation in the full cohort. Nevertheless, the concentrations measured in 1992-3 were still lower than those measured in 1997-9. This may indicate either improved folate status over time or insufficient correction for folate degradation. Although, the pABG assay has been demonstrated to be the best available method to determine folate status in samples stored for a longer time, about 1 % of folate measured as pABG is lost per year (32) . Therefore, actual folate concentrations of the participants at the time of blood withdrawal may have been underestimated, and differences between folate concentrations in 1992-3 and 1997-9 may have been smaller than observed. However, it seems unlikely that this would have changed the present results.
Comparison with the literature
The present main observation that a combination of plasma folate . 18·5 nmol/l with plasma vitamin B 12 , 274 pmol/l was associated with better cognitive performance contrasts the findings from the NHANES (7) and the Framingham Heart Study (11) . The NHANES showed worse cognitive performance in individuals with a combination of high plasma folate (. 59 nmol/l) with low vitamin B 12 (plasma vitamin B 12 , 148 pmol/l or MMA . 0·21 mmol/l) (7) . Several aspects related to study design might explain this discrepancy. First, the NHANES was conducted in an area of mandatory folic acid fortification, and the use of supplements containing folic acid was common, which led to increased concentrations of serum folate (53) and unmetabolised folic acid (54) . In contrast, supplement use was uncommon among Norwegian elderly, and mean folate intake including folate from supplements did not differ from folate intake from foods ( Table 1) . As a result, very high folate concentrations (.59 nmol/l) were present in 20·7 % of the NHANES study population (n 1459), compared with less than 1 % in the present study.
Second, the Norwegian elderly population had better vitamin B 12 status, with only 1·5 % suffering from vitamin B 12 deficiency (# 148 pmol/l), which was used as a cut-off by the NHANES. The unique combination of very high folate with very low vitamin B 12 status was present in a relatively small subgroup of forty-two individuals in the NHANES study, and even lower in the present study population (n 3). The better vitamin B 12 status of the present study population may be explained by an adequate dietary intake of vitamin B 12 (total mean intake 6·73 mg/d), probably related to the high intake of milk and fish in this population as shown previously (55) . The present findings also differed from the results of the Framingham Heart Study, unexposed to mandatory folic acid fortification, that showed a faster rate of decline in MMSE scores associated with having low vitamin B 12 plasma concentrations (,257 pmol/l) at high folate levels (. 20·2 nmol/l) (P interaction ,0·001) (11) . Cut-off levels used to define 'low' vitamin B 12 and 'high' folate status were similar to the present study; however, the Framingham Heart Study population showed more variation in plasma concentrations of both vitamin B 12 (18·6-695 pmol/l) and folate (0·54-149 nmol/l), which may explain the discrepant findings.
Overall, the contrasting findings between the NHANES study (7) and the present study, supported by the findings of the Framingham Heart Study (11) , suggest that only supraphysiologic folate status, resulting from fortification or supplemental folic acid intake, may exacerbate adverse cognitive consequences of low plasma vitamin B 12 status. This hypothesis is supported by recent data published by Morris (43) .
Metabolic effects of a combination of high folate and low vitamin B 12 status Some (7, 14, 56, 57) , but not all (13) studies have shown that elderly individuals with high folate and low vitamin B 12 status have a higher prevalence of anaemia, and higher concentrations of tHcy and MMA. It has been proposed that high folate concentrations may exacerbate the negative consequences of vitamin B 12 deficiency. It is possible that subjects with a combination of low vitamin B 12 and high folate status in these studies (7, 13, 14, 56, 57) suffered from severe vitamin B 12 deficiency due to disorders that affected vitamin B 12 absorption, such as pernicious anaemia (58, 59) . A recent study in healthy young adults without any medical conditions that could induce anaemia or affect folate or vitamin B 12 absorption did not observe any adverse effects of high folate concentrations on biochemical markers related to vitamin B 12 deficiency (60) . In our population, MMA concentrations were highest in participants with plasma vitamin B 12 in the lowest quartile and folate status in the highest quartile, which is in line with previous findings (14, 57) . In contrast, tHcy concentration was substantially lower in subjects with folate concentration in the highest quartile (. 18·5 nmol/l) when compared with the other quartiles, independent of vitamin B 12 status.
The view prevails that low vitamin B 12 status is associated with cognitive impairment (3) . For instance, six decades ago, it was proposed that high folate status in vitamin B 12 -deficient subjects may deteriorate cognitive performance (5, 6) . The adverse effect of high folate status may be confined to subjects with severe vitamin B 12 deficiency, leading to the methylfolate trap (61) . The Hordaland Health population was replete with vitamin B 12 , and only 4·9 % had plasma concentrations of vitamin B 12 , 150 pmol/l or MMA .0·37 mmol/l. Under these conditions, high folate levels may accelerate methionine synthesis, thereby increasing biological methylation including compounds involved in neurotransmission (62) . This is in line with the present observation that folate is associated with better cognitive performance, which remains significant even at vitamin B 12 concentrations ,274 pmol/l. We did not observe an interaction of folate with holoTC II and MMA. The utility of the vitamin B 12 markers MMA and holoTC II in relation to cognitive performance has been evaluated in some observational studies (3, 63) . The discrepancy between total vitamin B 12 and the other markers in the present study could perhaps be related to the fact that total vitamin B 12 may be a less sensitive indicator of vitamin B 12 status at concentrations above the traditional clinical cut-off level of 150 pmol/l due to buffering capacities of vitamin B 12 body stores (48) . Furthermore, similar to the present study, previous studies have observed poor correlations between the different indicators of vitamin B 12 status (64 -67) . The optimal combinations of markers, cut-off levels and assays for vitamin B 12 status assessment have been the topic of debate since many years. Mathematic models combining the results of different markers may provide the best alternative for assessing vitamin B 12 status in the future (49) .
Conclusion
In conclusion, the present large study population unexposed to mandatory or voluntary folic acid fortification showed that plasma folate, but not plasma vitamin B 12 , was associated with cognitive performance. Among the elderly participants with vitamin B 12 concentrations in the lower range, the association between plasma folate and cognitive performance was strongest. No interaction between folate and vitamin B 12 status was observed when considering more sensitive markers of vitamin B 12 status, MMA and holoTC II. Therefore, the clinical relevance of these observations is uncertain.
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